6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)

6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)

6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)

6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)

25 - SHL TELEMEDICINE LTD (0001166834) (Filer)

EFFECT - SHL TELEMEDICINE LTD (0001166834) (Filer)

S-8 POS - SHL TELEMEDICINE LTD (0001166834) (Filer)

6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)

POS AM - SHL TELEMEDICINE LTD (0001166834) (Filer)

6-K - SHL TELEMEDICINE LTD (0001166834) (Filer)

DocGo Inc. (NASDAQ:DCGO) ("DocGo" or the "Company"), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ:SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. This expanded collaboration, initially launched in the New York-New Jersey area, will now bring advanced cardiovascular diagnostics to patients' homes and underserved communities in additional markets across the country. According to the Journal of the American College of Cardiology, 46% of U.S. counties do not have any cardiologists1, highlighting the urgent need for accessible cardiovascular care. SHL

David Arnon held senior leadership and CEO roles within the healthcare insurance industry at Harel Insurance and Clal Insurance, two of the largest insurance groups in Israel SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level management experience within the healthcare insurance industry in Israel.

SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has clarified today that it is in discussions with Discount Capital Ltd. the investment arm of Israel Discount Bank, regarding a possible investment relating to SHL's Israeli activity. At this point, the parties have not yet taken any decision nor entered into any binding obligation with regard to the realization of such transaction. SHL will further inform the market as required. About SHL Telemedicine SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center service

Users in Israel will be able for the first time in the world to perform an at-home Biomarker blood test guided by SHL's medical team, following ECG tests using The SmartHeart® for Rapid Heart Attack Detection. SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is proud to announce that it has expanded its offering in Israel to include the groundbreaking ability to perform at-home Biomarker blood tests. This diagnostic tool is designed to rapidly identify cardiac markers for detection of a heart attack, transforming emergency cardiac care with speed and precision. Following concerns o

A revolutionary at-home 12-lead ECG service with 24/7 cardiologist review and telehealth service now fully available in the US. SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is thrilled to announce that it recently officially launched it's SmartHeart® membership program in the US. This announcement comes after the highly successful soft launch that was announced in November 2023, which exceeded the company's expectations, demonstrating substantial demand and positive customer feedback. Erez Nachtomy, CEO of SHL Telemedicine commented: "The official launch marks a significant m

SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX Swiss Exchange: SHLTN))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation. In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL's Israel operation maintained stability and profitability, reflecting the company's solid foundation in its home market. In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart® ECG platform, enhancing access to r

Groundbreaking Study reveals a 76% drop in hospital readmissions and a 41% decrease in Emergency Department visits, underscoring SHL and SmartHeart®'s pivotal role in remote cardiac care SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce the groundbreaking full results of the Imperial College London TELE-ACS Trial. The randomized clinical trial showcased, among other things, how SHL's SmartHeart® 12-lead ECG technology can significantly reduce hospital readmissions and ED visits for post-MI (heart attack) patients at home. This press release features multimedia.

SHL's SmartHeart portable 12-lead ECG technology successfully participated in the U.S. Army's Project Convergence – Capstone 4 experiment (PC-C4), demonstrating exceptional reliability, user-friendliness, and effectiveness, even in extreme scenarios. SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions is pleased to share that in a remarkable display of innovation and operational excellence, the Company's SmartHeart®, portable 12-lead ECG technology showcased its unparalleled capabilities and successfully participated in Project Convergence – Capstone 4 (PC-C4), the largest, two-phase, "i

SHL Telemedicine Ltd. ((SIX Swiss Exchange: SHLTN, NASDAQ:SHLT) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET. The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for the same day as following: Date: Wednesday, April 17, 2024 Time: 4 pm CET / 10 am ET / 5 pm Israel Time The conference call can be accessed live via the below dial-in numbers: From Europe   +41 (0) 58 310 5

The selection of the TELE-ACS trial results for presentation at ACC 24 highlights the pioneering achievements of Imperial College London and SHL in advancing the field of telemedicine SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, is excited to announce that the full results of the Imperial College London TELE-ACS clinical trial have been selected for presentation at the prestigious American College of Cardiology's 24th Annual Scientific Session & Expo Late-Breaking Clinical Trials Sessions (ACC 24 LBCT) in Atlanta. The full results of the TELE-ACS trial, led by Dr. Ramzi Khamis

David Arnon held senior leadership and CEO roles within the healthcare insurance industry at Harel Insurance and Clal Insurance, two of the largest insurance groups in Israel SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX: SHLTN, ))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, has announced today that it has appointed Mr. David Arnon as CEO of the Company. He will join SHL Telemedicine and assume the role on August 6, 2024, succeeding Erez Nachtomy, who, as previously announced, will step down as CEO. Mr. Arnon has over 17 years of commercial and executive level management experience within the healthcare insurance industry in Israel.

SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX Swiss Exchange: SHLTN))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation. In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL's Israel operation maintained stability and profitability, reflecting the company's solid foundation in its home market. In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart® ECG platform, enhancing access to r

SHL Telemedicine Ltd. ((SIX Swiss Exchange: SHLTN, NASDAQ:SHLT) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will publish its results for 2023 on Wednesday, April 17, 2024 at 7 am CET. The conference call for investors, journalists, and analysts to discuss the annual results 2023 will be hosted by Yariv Alroy, Chairman, Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for the same day as following: Date: Wednesday, April 17, 2024 Time: 4 pm CET / 10 am ET / 5 pm Israel Time The conference call can be accessed live via the below dial-in numbers: From Europe   +41 (0) 58 310 5

Regulatory News: SHL Telemedicine Ltd. (NASDAQ:SHLT, SIX Swiss Exchange: SHLTN))) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year 2023, emphasizing stable revenues and strategic growth initiatives. In H1 2023, SHL maintained stable revenues while making significant strategic advancements across all operations. The Company made substantial investments in Germany, where it launched the Doctors' Virtual Visits services and then witnessed a steady increase in the adoption of the service. In the US, the Company witnessed the growing utilization and distribution of the SmartHeart® ECG platform by

TEL AVIV, Israel, ZURICH and NEW YORK, Sept. 6, 2023 /PRNewswire/ --  SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN) (NASDAQ:SHLT) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, today announced that it will issue its Half-year 2023 results before market opens on Thursday, September 21, 2023. The conference call for investors, journalists, and analysts to discuss the half-year results 2023 will be hosted by Erez Nachtomy, CEO, and Amir Hai, CFO, and has been scheduled for: Date: Thursday, 21 September 2023 Time: 4 pm CET / 10 am ET / 5 pm Israel Time The conference call can be accessed live via the dial-in numbers: From Europe      

SC 13G - SHL TELEMEDICINE LTD (0001166834) (Subject)

SC 13G - SHL TELEMEDICINE LTD (0001166834) (Subject)